Imatinib mesylate is a tyrosine kinase inhibitor used in the treatment of several malignancies. Its use, however, is associated with a number of toxic effects including adverse cutaneous reactions. Herein, we present a case of facial cystic acne in a patient receiving imatinib therapy for chronic myelocytic leukemia. This side effect resolved with cessation of therapy. To the best of our knowledge, this clinical entity has never been previously reported in the medical literature.
JabbourEKantarjianH. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. AJH2016; 91: 253–265.
2.
AlexandrescuDTDasanuCAFarzanmehrHet al.Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J2008; 14: 7–7.
3.
VermaPSingelASharmaS. Imatinib mesylate-induced cutaneous rash masquerading as pityriasis rosea of Gilbert. Indian J Dermatol2014; 59: 311–312.
4.
KuraishiNNagaiYHasegawaMet al.Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report. Acta Derm Venereol2010; 90: 73–76.
5.
ScheinfeldN. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol2006; 5: 228–231.
6.
DemirciUCoskunUErdemO. Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient. J Oncol Pharm Pract2011; 17: 285–287.
